Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26686
Abstract: Ponatinib, the only third‐generation pan‐BCR::ABL1 inhibitor with activity against all known BCR::ABL1 mutations including T315I, has demonstrated deep and durable responses in patients with chronic‐phase chronic myeloid leukemia (CP‐CML) resistant to prior second‐generation (2G) TKI… read more here.
Keywords: chronic myeloid; leukemia; generation; phase chronic ... See more keywords
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27229
Abstract: Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR). read more here.
Keywords: accelerated phase; phase chronic; novo accelerated; chronic myeloid ... See more keywords
Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.10.067
Abstract: Morphine is an opioid analgesic drug routinely used in the postoperative period for pain management in cancer patients. In this work, we analyzed the effects of morphine on leukemia cells at all stages of development… read more here.
Keywords: blast phase; cml; morphine; leukemia cells ... See more keywords
A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-89851-y
Abstract: The T315I mutation poses a significant threat to patients with chronic phase chronic myeloid leukemia (CP-CML). This study aimed to establish a nomogram to predict the risk of T315I mutation in CP-CML patients. The training… read more here.
Keywords: chronic phase; phase chronic; t315i free; free survival ... See more keywords
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Medicine"
DOI: 10.1080/07853890.2022.2069280
Abstract: Abstract Introduction Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs). Materials and methods We retrospectively analysed the clinical features, treatment… read more here.
Keywords: outcomes adolescents; adolescents young; chronic myeloid; young adults ... See more keywords
Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutical Biology"
DOI: 10.1080/13880209.2022.2044862
Abstract: Abstract Context Resistance to BCR-ABL tyrosine kinase inhibitor (TKI) is the cause of treatment failure in blast phase chronic myeloid leukaemia (BP-CML). Agents that act synergistically with BCR-ABL TKI are required to improve response. Objective… read more here.
Keywords: combination; blast phase; myeloid leukaemia; tki ... See more keywords
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-0957
Abstract: Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted… read more here.
Keywords: phase; newly diagnosed; radotinib; chronic phase ... See more keywords
Efficacy and safety of pegylated interferon alfa-2b combined with tyrosine kinase inhibitors in chronic Phase chronic myeloid leukemia patients with TKI resistance or intolerance
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7295
Abstract: Background In the TKI era, long-term survival of chronic phase chronic myeloid leukemia (CP-CML) patients approaches that of the general population. However, approximately 10-15% of patients develop TKI resistance or intolerance. Optimizing therapy for this… read more here.
Keywords: chronic phase; chronic myeloid; phase chronic; myeloid leukemia ... See more keywords
Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024024657
Abstract: Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for chronic phase chronic myeloid leukaemia (CP-CML) patients failing ≥2 prior lines of therapy. The Australasian Leukaemia & Lymphoma Group (ALLG) conducted the ASCEND study to assess… read more here.
Keywords: chronic phase; treatment; phase chronic; response ... See more keywords
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1101738
Abstract: Introduction Flumatinib is a novel, oral breakpoint cluster region-abelson (BCR-ABL) tyrosine kinase inhibitor that has demonstrated manageable safety and promising efficacy in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML). Methods This… read more here.
Keywords: myeloid leukemia; chronic myeloid; flumatinib; multiple dose ... See more keywords